- Home
- RPD vs TVTX Comparison
RPD vs TVTX Comparison
Compare RPD & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPD
- TVTX
- Stock Information
- Founded
- RPD 2000
- TVTX 2008
- Country
- RPD United States
- TVTX United States
- Employees
- RPD N/A
- TVTX N/A
- Industry
- RPD Computer Software: Prepackaged Software
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- RPD Technology
- TVTX Health Care
- Exchange
- RPD Nasdaq
- TVTX Nasdaq
- Market Cap
- RPD 1.5B
- TVTX 1.4B
- IPO Year
- RPD 2015
- TVTX N/A
- Fundamental
- Price
- RPD $22.71
- TVTX $15.32
- Analyst Decision
- RPD Hold
- TVTX Strong Buy
- Analyst Count
- RPD 20
- TVTX 16
- Target Price
- RPD $32.61
- TVTX $33.33
- AVG Volume (30 Days)
- RPD 730.2K
- TVTX 1.4M
- Earning Date
- RPD 08-07-2025
- TVTX 08-04-2025
- Dividend Yield
- RPD N/A
- TVTX N/A
- EPS Growth
- RPD N/A
- TVTX N/A
- EPS
- RPD 0.41
- TVTX N/A
- Revenue
- RPD $849,159,000.00
- TVTX $273,533,000.00
- Revenue This Year
- RPD $2.78
- TVTX $73.99
- Revenue Next Year
- RPD $3.91
- TVTX $42.00
- P/E Ratio
- RPD $55.88
- TVTX N/A
- Revenue Growth
- RPD 6.19
- TVTX 75.65
- 52 Week Low
- RPD $21.61
- TVTX $7.93
- 52 Week High
- RPD $44.48
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- RPD 44.97
- TVTX 45.07
- Support Level
- RPD $22.30
- TVTX $15.34
- Resistance Level
- RPD $23.26
- TVTX $16.17
- Average True Range (ATR)
- RPD 0.76
- TVTX 0.67
- MACD
- RPD -0.06
- TVTX -0.03
- Stochastic Oscillator
- RPD 14.91
- TVTX 23.95
About RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.